1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Market Spotlight: Neuropathic Pain

Market Spotlight: Neuropathic Pain

  • March 2018
  • 36 pages
  • ID: 5182409
  • Format: PDF
  • By Datamonitor Healthcare


Table of Contents

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways 
Datamonitor Healthcare estimates that in 2016, there were 385.0 million prevalent cases of neuropathic pain in adults aged 20 years and older worldwide, and forecasts that number to increase to 431.3 million prevalent cases by 2025. 

Asia is estimated to have had the largest number of prevalent cases in 2016, but the lowest prevalence proportion (96.4 million cases; 3.20%). 

The majority of industry-sponsored drugs in active clinical development for neuropathic pain are in Phase I, with just one therapy in Phase III. 

Therapies in mid- and late-stage development for neuropathic pain focus on a variety of targets such as opioid receptors, sodium channels, TRPV1, and NMDA receptors. The majority of pipeline drugs in mid- and late-stage development for neuropathic pain are administered orally, with the remainder including intravenous and topical formulations. 

Sodium channel antagonists Carbatrol (carbamazepine; Shire) and Tegretol (carbamazepine; Novartis), Pfizer’s calcium channel agonist Lyrica (pregabalin), and Acorda’s transient receptor potential vanilloid receptor 1 agonist Qutenza (capsaicin) are the only marketed drugs available for neuropathic pain. These marketed drugs are administered via the oral route, except for Qutenza, which is available as a topical formulation. 

There were 21 licensing and asset acquisition activities involving neuropathic pain drugs during 2012–17, seven of which occurred in 2015. The exclusive licensing agreement in 2015 between Depomed and Janssen for the acquisition of US rights to Nucynta for $1.05bn was the largest deal during 2012–17. 
Lyrica’s sales ranked highest among drugs available for neuropathic pain during 2012–16, and revenues are expected to remain high until its patent expiry at the end of 2018. 

The distribution of clinical trials across Phase I–IV indicates that the majority of trials have been in the early and mid-phases of development, with 68% of trials in Phase I–II, and 32% in Phase III–IV. 
The US has a substantial lead in the number of neuropathic pain clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia. 

Pfizer has by far the highest number of completed clinical trials for neuropathic pain, and has also had the highest number of trials for neuropathic pain at all phases of development.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Collagenase 3 - Pipeline Review, H2 2019

Collagenase 3 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Collagenase 3 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Collagenase 3 - Pipeline Review, H2 2019’; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) ...

Beta Nerve Growth Factor - Pipeline Review, H1 2020

Beta Nerve Growth Factor - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Beta Nerve Growth Factor - Pipeline Review, H1 2020SummaryBeta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, ...

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2020, provides an overview of the ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on